PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

NCT05105152 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: PLAT-08
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).

Conditions

Acute Myeloid Leukemia; Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse

Outcome Measures

Primary Outcomes (2)

• Adverse events associated with SC-DARIC33 cell product infusions will be assessed

  The type, frequency, severity, and duration of adverse events will be summarized

  28 days post-infusion

• Ability to successfully manufacture SC-DARIC33

  Measure of the number of successfully manufactured SC-DARIC33 products

  28 days

Secondary Outcomes (1)

• Acute Myeloid Leukemia response to SC-DARIC in subjects with relapsed or refractory CD33+ myeloid leukemia will be assessed

  28 days post-infusion

Study Arms (1)

DARIC-33

EXPERIMENTAL

Biological: SC-DARIC33

Interventions

SC-DARIC33 BIOLOGICAL

Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration

DARIC-33

Eligibility Criteria

• Age: Up to 30 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Subject age ≤ 30 years. The first three enrolled subjects must be ≥ 18 years of age.
• AML that expresses CD33 by flow cytometry and meets one of the below definitions:
• For subjects who have previously received an allogeneic HCT, any evidence of AML re-emergence post HCT detectable by flow cytometry
• First relapse of AML ≤ 6 months of initial diagnosis
• First relapse of AML \> 6 months after initial diagnosis, with MRD of \>0.1% by flow cytometry (MPF) after at least one re-induction (single cycle) attempt
• Second or greater relapse AML
• Refractory AML, defined as \>1% leukemic cells determined by flow cytometry after 2 cycles of induction chemotherapy
• Able to tolerate apheresis, or subject with sufficient existing apheresis product or T cells for manufacturing investigational product.
• Life expectancy ≥ 8 weeks
• Has an appropriate stem cell donor source identified
• Lansky performance status score of ≥ 50 for subjects \<16 years of age or Karnofsky score ≥ 50 for subjects ≥ 16 years. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status
• If a subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of DARIC T cells, the subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy:
• a. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued ≥ 7 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period b. Must be ≥ 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued ≥ 7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be discontinued ≥ 3 days prior to enrollment e. Hydroxyurea: must be discontinued ≥ 1 day prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR ii. must be at least 60 days from most recent gene modified cell therapy
• Adequate organ function as indicated by:
• Renal: Serum creatinine ≤ 1.5 X the upper limit of normal (ULN)

You may not qualify if:

• Active malignancy other than acute myeloid leukemia
• History of symptomatic non-AML CNS disease or ongoing symptomatic CNS disease requiring medical intervention, including paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder (subjects with non-febrile seizure disorder controlled on anti-epileptic medication and without seizure activity within 1 month are eligible).
• CNS AML involvement that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and DARIC T cell infusion
• If history of allogeneic stem cell transplant: active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment
• Presence of active severe infection, defined as:
• i. positive blood culture within 48 hours of enrollment, OR ii. fever above 38.2° C, AND clinical signs of infection within 48 hours of enrollment
• Primary immunodeficiency syndrome
• Subject has received prior virotherapy
• Pregnant or breastfeeding
• Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow-up period, required if DARIC T cell therapy is administered
• Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol
• Considered by the investigator to be unable to tolerate a lymphodepleting regimen
• Subject has a contraindication to receiving rapamycin

Sponsors & Collaborators

• Seattle Children's Hospital: lead
• Regeneron Pharmaceuticals: collaborator

Study Sites (1)

Seattle Children's Hospital

Seattle, Washington, 98105, United States

RECRUITING

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Adam Lamble, MD

CONTACT

206-986-2106; CBDCIntake@seattlechildrens.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Director, Seattle Children's Therapeutics

Model Details: Phase I open-label, dose-finding study employing the Bayesian optimal interval (BOIN) design

Study Record Dates

• First Submitted: October 7, 2021
• First Posted: November 3, 2021
• Study Start: November 29, 2021
• Primary Completion (Estimated): February 28, 2028
• Study Completion (Estimated): January 31, 2041
• Last Updated: December 23, 2025

Record last verified: 2025-12

Locations

US (1)